Consistent with this scenario is a recent study demonstrating that Tau dysfunction and neurofibrillary tangle formation are abolished by silencing GSK3β activity in Alzheimer's disease transgenic mouse models [36], and many other observations indicate that PKC activators can exert antidementic effects during premature ageing of the brain [41, 53–56]. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.